Search Results

Samsung Biologics today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.

LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.

LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC).

BostonGene and LegoChem Biosciences, Inc. announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers.

LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.

NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its firstof five exclusive, target-specific optionswith LegoChem Biosciences (LCB, KOSDAQ: 141080)for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.

The snacks and confectionery giant has been seeking to enter the biopharmaceuticals space in recent years.

LegoChem Biosciences Inc. and Glycotope GmbH have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies.

NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.